{
    "score": [
        0.5
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "weekly analysts ' ratings updates for illumina ."
    ],
    "id": "998629.train",
    "article": [
        "a number of research firms have changed their ratings and price targets for illumina : 1/16/2018 -- illumina was given a new $ 275.00 price target on by analysts at deutsche bank ag . they now have a `` buy '' rating on the stock . 1/9/2018 -- illumina had its `` positive '' rating reaffirmed by analysts at wells fargo & co. . they now have a $ 260.00 price target on the stock , up previously from $ 250.00.1 / 9/2018 -- illumina had its `` buy '' rating reaffirmed by analysts at piper jaffray companies . they now have a $ 269.00 price target on the stock . ",
        "1/5/2018 -- illumina was downgraded by analysts at william blair from an `` outperform '' rating to a `` market perform '' rating . 1/5/2018 -- illumina was upgraded by analysts at bidaskclub from a `` hold '' rating to a `` buy '' rating . 1/5/2018 -- illumina is now covered by analysts at btig research . they set a `` neutral '' rating on the stock . 1/4/2018 -- illumina had its price target raised by analysts at piper jaffray companies to $ 274.00 . they now have an `` overweight '' rating on the stock . 1/3/2018 -- illumina is now covered by analysts at evercore isi . ",
        "they set an `` outperform '' rating and a $ 250.00 price target on the stock . 1/2/2018 -- illumina was upgraded by analysts at wells fargo & co from a `` market perform '' rating to an `` outperform '' rating . they now have a $ 205.00 price target on the stock . 12/26/2017 -- illumina was downgraded by analysts at zacks investment research from a `` buy '' rating to a `` hold '' rating . according to zacks , `` post a promising third-quarter show , we expect illumina to maintain its growth momentum on continued uptake of sequencing consumables , instruments and microarray portfolios . ",
        "management is also hopeful that recent launches like novaseq s4 flow cell and reagent kit for its novaseq 6000 system will drive demand for novaseq . we look forward to the launch of novaseq xp workflow . also , the company 's launch of nextera dna flex buoys optimism . moreover , the company recently partnered with telegraph hill partners to set up an independent entity . accordingly , over the last three months , illumina has been trading above the broader industry . on the flip side , weak margins owing to the novaseq launch , higher array services revenues and unfavorable product mix within sequencing consumables will continue to act as deterrents . '' ",
        "12/14/2017 -- illumina had its price target raised by analysts at morgan stanley from $ 122.00 to $ 135.00 . they now have an `` underweight '' rating on the stock . 12/6/2017 -- illumina was downgraded by analysts at bidaskclub from a `` buy '' rating to a `` hold '' rating . 12/5/2017 -- illumina was upgraded by analysts at zacks investment research from a `` hold '' rating to a `` buy '' rating . they now have a $ 252.00 price target on the stock . according to zacks , `` post a promising third-quarter show , we expect illumina to maintain its growth momentum on continued uptake of sequencing consumables , instruments and microarray portfolios . ",
        "management is also hopeful that recent launches like novaseq s4 flow cell and reagent kit for its novaseq 6000 system will drive demand for novaseq . we look forward to the launch of novaseq xp workflow . also , the company 's launch of nextera dna flex buoys optimism . moreover , the company recently partnered with telegraph hill partners to set up an independent entity . accordingly , over the last three months , illumina has been trading above the broader industry . on the flip side , weak margins owing to the novaseq launch , higher array services revenues and unfavorable product mix within sequencing consumables will continue to act as deterrents . '' ",
        "illumina , inc. . traded up $ 4.68 during mid-day trading on tuesday , hitting $ 244.72 . the company 's stock had a trading volume of 975,700 shares , compared to its average volume of 1,170,022 . illumina , inc. . has a 1 year low of $ 156.50 and a 1 year high of $ 245.96 . the company has a debt-to-equity ratio of 0.41 , a current ratio of 4.22 and a quick ratio of 3.73 . the stock has a market cap of $ 35,250.00 , a p/e ratio of 46.17 , a price-to-earnings-growth ratio of 3.30 and a beta of 0.79 . ",
        "illumina last posted its earnings results on tuesday , october 24th . the life sciences company reported $ 1.11 earnings per share for the quarter , topping analysts ' consensus estimates of $ 0.99 by $ 0.12 . illumina had a return on equity of 19.42 % and a net margin of 30.34 % . the firm had revenue of $ 714.00 million for the quarter , compared to the consensus estimate of $ 692.77 million . during the same quarter in the prior year , the business earned $ 0.97 eps . the business 's revenue for the quarter was up 17.6 % on a year-over-year basis . ",
        "research analysts forecast that illumina , inc. . will post 3.76 earnings per share for the current year . in other illumina news , director jay t. flatley sold 20,000 shares of the company 's stock in a transaction that occurred on tuesday , october 24th . the stock was sold at an average price of $ 210.43 , for a total transaction of $ 4,208,600.00 . following the transaction , the director now owns 539,176 shares in the company , valued at approximately $ 113,458,805.68 . the transaction was disclosed in a document filed with the securities & exchange commission , which can be accessed through this hyperlink . ",
        "also , evp omead ostadan sold 3,540 shares of the company 's stock in a transaction that occurred on friday , december 1st . the stock was sold at an average price of $ 226.91 , for a total value of $ 803,261.40 . following the transaction , the executive vice president now owns 26,827 shares in the company , valued at approximately $ 6,087,314.57 . the disclosure for this sale can be found here . insiders have sold a total of 137,671 shares of company stock worth $ 29,485,768 in the last quarter . company insiders own 0.89 % of the company 's stock . ",
        "illumina , inc is a provider of sequencing - and array-based solutions for genetic analysis . the company operates through two segments : core illumina and the consolidated variable interest entities , which include the activities of grail , inc and helix holdings i , llc . core illumina consists of its core operations .   "
    ]
}